APDN רווח נקי למניה (EPS TTM) Applied DNA Corp

Applied DNA Sciences (APDN) dominates PCR labeling for brand protection, as evidenced by the rolling annual net income per share, where the indicator level stands at -915.62. The high qualification of biologists supports growth, although competition with tech giants and dependence on LinearRx patents create certain risks for business margins.

Filtering out market noise is critical for capital preservation amid volatility. This metric reflects the final net income distributed per common share over a rolling year. The earnings per share (EPS) trend over the last 12 months allows investors to distinguish a speculative bounce from a genuine recovery of fundamental value. For Applied DNA Sciences (APDN), this indicator confirms the effectiveness of implementing DNA tracking within B2B/B2G segments. Growth in this metric would signal the monetization of the mandatory transition of US corporations to supply chain labeling systems.